Mr. Chand Jagpal reports

ALBERT LABS WELCOMES DR. SHABIR HASHAM TO BOARD OF DIRECTORS

Albert Labs International Corp. has appointed Dr. Shabir Hasham to its board of directors. With an impressive 20 years of distinguished industry experience, Dr. Hasham brings a wealth of expertise to guide Albert Labs in its mission to revolutionize mental health solutions.

Regulatory expertise: Dr. Hasham's exceptional career is marked by his proficiency in navigating regulatory bodies, including the Food and Drug Administration and Medicines and Healthcare products Regulatory Agency, ensuring successful product launches and compliance. His regulatory acumen aligns seamlessly with Albert Labs' commitment to delivering innovative mental health solutions.

Neuroscience franchise expertise: As the former EU medical director for the neuroscience franchise at Novartis, Dr. Hasham played a pivotal role in advancing pharmaceutical solutions. His leadership is a testament to his deep understanding of the complexities involved in bringing transformative medicines to market.

Team collaboration: Dr. Hasham's arrival marks a reunion with former team members, including chief medical officer Dr. Malcolm Barrett Johnson and chief operations officer Santoke Naal. His past collaborations with these key individuals, particularly during their tenure at Novartis, underscore Dr. Hasham's exceptional ability to drive successful outcomes in a collaborative environment.

Expertise in pharma leadership and progressive role: In addition to his 20 years of experience, Dr. Hasham will be progressively taking on an increased leadership role within Albert Labs. His informal leadership style, combined with strategic planning and operational excellence, aligns seamlessly with the company's vision for transformative solutions in mental health pharmaceuticals.

Biotechnology and health care investment funds: Dr. Hasham possesses a unique proficiency in dealing with biotechnology and health care investment funds. His strategic insights have effectively guided investments, contributing to the success of various projects. Dr. Hasham's ability to communicate complex ideas in the right manner has been instrumental in securing support from investment entities, and ensuring alignment with organizational goals. Albert Labs looks forward to leveraging Dr. Hasham's multifaceted expertise as the company continues its pursuit of excellence in mental health pharmaceuticals.

About Albert Labs International Corp.

Albert Labs is a fully integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which patient needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast-track clinical pathway focusing on real-world evidence (RWE). RWE studies are a recognized clinical pathway, heavily used in oncology and, recently, in the successful development of COVID-19 vaccines.

Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly one million new sufferers each year. From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide.

The company's goal is to deliver effective medicines to those who suffer with their mental health in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.

We seek Safe Harbor.